Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Ex-JPMA Chief Aoki Wants to See Japan’s Gilead, Govt Leadership in Consolidation
July 3, 2017
-
REGULATORY MHLW to Soon Present Criteria for Drugs Subject to Optimal Use Guidelines
June 30, 2017
-
REGULATORY “CEA” Scheme to Be Initially Introduced for Post-Listing Price Adjustment, Targeting Innovative Products with Big Market: Chuikyo
June 29, 2017
-
REGULATORY Chuikyo Agrees to “Reward Innovation More” when Using Cost Calculation Pricing Method
June 29, 2017
-
BUSINESS Drug Makers Moving to Outsource “Pharmaceutical Scouting” to Seek Efficiency: Ex-Sanofi Exec
June 28, 2017
-
BUSINESS Pfizer Japan Ups Oncology Sales Force, Reorganizes It into Blood, Solid Cancer Groups
June 27, 2017
-
BUSINESS Sumitomo Dainippon’s Napabucasin Stumbles on PIII Gastric Cancer Study
June 27, 2017
-
BUSINESS Daiichi Sankyo Confident of Achieving US$1 Billion Sales for Edoxaban
June 26, 2017
-
REGULATORY Wakayama Substance Supplier Mixed in China-Made Ingredient; MHLW Sees No Safety Concerns
June 23, 2017
-
BUSINESS Development Race Heating Up for HIF-PH Inhibitors, Promising Alternative to ESAs in Renal Anemia Space?
June 22, 2017
-
BUSINESS Amgen Astellas Biopharma Gearing Up for 2020 Takeoff as Stand-Alone Subsidiary
June 20, 2017
-
ORGANIZATION FPMAJ Calls for Maintaining Prices for On-Patent Drugs, Lower Price Reduction Rates in Off-Year Revisions
June 19, 2017
-
BUSINESS Biogen Japan Upbeat on Tecfidera, Near-Approval Nusinersen, Sakigake Boost for Aducanumab
June 19, 2017
-
TRENDS Authorized Generics Solidifying Their Presence in Japan Gx Market
June 16, 2017
-
REGULATORY 1st Generics for 13 APIs to Join NHI Price List on June 16; Micardis, Abilify Face Competition
June 15, 2017
-
REGULATORY (Update) Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium, Tiered Premiums Eyed: Chuikyo
June 15, 2017
-
REGULATORY Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium: Chuikyo
June 14, 2017
-
ACADEMIA Japanese Society of Hypertension to Verify Results of SPRINT Study
June 14, 2017
-
ORGANIZATION JGA Appreciates Tweaked Honebuto Text on Generics, 80% Goal Achievable on Production Basis
June 13, 2017
-
REGULATORY Govt’s Regulatory Reform Plan Embraces Review of 14-Day Prescription Limit
June 12, 2017
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…